Could a cheap arthritis drug replace harmful steroids for transplant patients?
NCT ID NCT04932564
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times
Summary
This study tested leflunomide, a drug used for rheumatoid arthritis, as a first treatment for musculoskeletal graft-versus-host disease (GVHD) — a condition where donor cells attack a patient's joints and muscles after a stem cell transplant. The goal was to see if leflunomide could control the disease with fewer side effects than standard steroid therapy. Only one person enrolled before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVHD, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer
Navi Mumbai, Maharashtra, 410210, India
Conditions
Explore the condition pages connected to this study.